Accelerating anticancer drug development — opportunities and trade-offs
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Accelerating anticancer drug development — opportunities and trade-offs
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 15, Issue 12, Pages 777-786
Publisher
Springer Nature America, Inc
Online
2018-10-01
DOI
10.1038/s41571-018-0102-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Estimation of clinical trial success rates and related parameters
- (2018) Chi Heem Wong et al. BIOSTATISTICS
- Real-World Evidence In Support Of Precision Medicine: Clinico-Genomic Cancer Data As A Case Study
- (2018) Vineeta Agarwala et al. HEALTH AFFAIRS
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Positron Emission Tomography/Computed Tomography–Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer
- (2018) Josef J. Fox et al. JAMA Oncology
- A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics
- (2018) Julia A. Beaver et al. JAMA Oncology
- Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
- (2018) Tareq Al Baghdadi et al. JOURNAL OF CLINICAL ONCOLOGY
- Untapped Potential of Observational Research to Inform Clinical Decision Making: American Society of Clinical Oncology Research Statement
- (2017) Kala Visvanathan et al. JOURNAL OF CLINICAL ONCOLOGY
- Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement
- (2017) Edward S. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Finding the Evidence in Real-World Evidence: Moving from Data to Information to Knowledge
- (2017) Richard L. Schilsky JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Real-world Data for Clinical Evidence Generation in Oncology
- (2017) Sean Khozin et al. JNCI-Journal of the National Cancer Institute
- A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer
- (2017) Daniel A Goldstein et al. JNCI-Journal of the National Cancer Institute
- Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
- (2017) Janet Woodcock et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies
- (2017) Loren S. Michel et al. RADIOLOGY
- Evaluating Frameworks That Provide Value Measures for Health Care Interventions
- (2017) Jeanne S. Mandelblatt et al. VALUE IN HEALTH
- Real-world Data for Clinical Evidence Generation in Oncology
- (2017) Sean Khozin et al. JNCI-Journal of the National Cancer Institute
- A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer
- (2017) Daniel A Goldstein et al. JNCI-Journal of the National Cancer Institute
- Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle
- (2016) P. A. Ja nne et al. CLINICAL CANCER RESEARCH
- 18 F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials
- (2016) Yingbing Wang et al. CLINICAL CANCER RESEARCH
- A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Non-Small Cell Lung Cancer
- (2016) GK Raju et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Benefit-Risk Analysis for Decision-Making: An Approach
- (2016) GK Raju et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Imaging biomarker roadmap for cancer studies
- (2016) James P. B. O'Connor et al. Nature Reviews Clinical Oncology
- Seamless Oncology-Drug Development
- (2016) Tatiana M. Prowell et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials
- (2016) Mourad Tighiouart et al. STATISTICS IN MEDICINE
- Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results
- (2016) Thomas J. Hwang et al. JAMA Internal Medicine
- Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms
- (2016) Maria Schwaederle et al. JAMA Oncology
- Advancing Clinical Trials to Streamline Drug Development
- (2015) S. E. Bates et al. CLINICAL CANCER RESEARCH
- Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials
- (2015) M. R. Theoret et al. CLINICAL CANCER RESEARCH
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- Emerging innovations in clinical trial design
- (2015) DA Berry CLINICAL PHARMACOLOGY & THERAPEUTICS
- Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval
- (2015) Denis L. Fontes Jardim et al. JNCI-Journal of the National Cancer Institute
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval
- (2015) Denis L. Fontes Jardim et al. JNCI-Journal of the National Cancer Institute
- Five Years of Cancer Drug Approvals
- (2015) Sham Mailankody et al. JAMA Oncology
- Pembrolizumab
- (2015) Leila Khoja et al. Journal for ImmunoTherapy of Cancer
- Optimizing Dosing of Oncology Drugs
- (2014) L Minasian et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Early phase clinical trials to identify optimal dosing and safety
- (2014) Natalie Cook et al. Molecular Oncology
- FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements
- (2014) D. Kazandjian et al. ONCOLOGIST
- Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control
- (2014) Mourad Tighiouart et al. STATISTICS IN MEDICINE
- Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer
- (2013) Dana E. Rathkopf et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of response endpoints with survival outcomes in multiple myeloma
- (2013) S Lonial et al. LEUKEMIA
- Toward Patient-Centered Drug Development in Oncology
- (2013) Ethan Basch NEW ENGLAND JOURNAL OF MEDICINE
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial
- (2012) Pasi A. Jänne et al. JOURNAL OF CLINICAL ONCOLOGY
- Assumptions of Expected Benefits in Randomized Phase III Trials Evaluating Systemic Treatments for Cancer
- (2012) H. K. Gan et al. JNCI-Journal of the National Cancer Institute
- Crizotinib for the Treatment of ALK -Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology
- (2012) Sai-Hong Ignatius Ou et al. ONCOLOGIST
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
- (2011) Masahiro Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Microsatellite instability in colorectal cancer—the stable evidence
- (2010) Eduardo Vilar et al. Nature Reviews Clinical Oncology
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All
- (2009) Sumithra J. Mandrekar et al. Journal of Biopharmaceutical Statistics
- Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation
- (2009) Leisha A. Emens et al. JOURNAL OF CLINICAL ONCOLOGY
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
- (2009) R. L. Wahl et al. JOURNAL OF NUCLEAR MEDICINE
- Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
- (2009) Peter B. Bach NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started